TNFRSF10A Recombinant Proteins
TNFRSF10A, also known as Tumor Necrosis Factor Receptor Superfamily Member 10A, or DR4 (Death Receptor 4), is a crucial receptor in the apoptosis pathway. It binds to the TNF-related apoptosis-inducing ligand (TRAIL), triggering the extrinsic apoptotic signaling cascade. This receptor is vital in immune regulation and tumor suppression.
Content of TNFRSF10A Recombinant Protein
- Structure:
- Typically contains the extracellular domain of TNFRSF10A, facilitating its binding to TRAIL.
- Expression systems such as E. coli, HEK293, or CHO cells are used, with mammalian systems offering glycosylation for native-like properties.
- Physical and Biochemical Properties:
- Molecular Weight: Approximately 20–30 kDa, depending on glycosylation status.
- Solubility: Highly soluble in aqueous buffers, maintaining structural integrity.
- Activity: Preserved ability to bind TRAIL with high affinity, verified through functional assays.
Applications of TNFRSF10A Recombinant Protein
- Cancer Research:
- Used to investigate TRAIL-induced apoptosis in cancer cells and the role of DR4 in tumor suppression.
- Supports the development of targeted therapies aimed at DR4-mediated apoptosis.
- Explores resistance mechanisms in tumors to TRAIL-induced apoptosis.
- Immunology:
- Studies the role of DR4 in immune-mediated cytotoxicity and immune evasion by cancer cells.
- Analyzes interactions between TNFRSF10A and other apoptotic and immune signaling proteins.
- Drug Development:
- Serves as a target for small molecules or monoclonal antibodies designed to enhance TRAIL-DR4 interactions.
- Enables testing of TRAIL agonists for their therapeutic potential in oncology.
Recombinant TNFRSF10A proteins are indispensable for understanding apoptosis and immune signaling, offering a robust platform for cancer research, therapeutic development, and signal transduction studies. These proteins’ reliability and high functional activity make them critical tools in translational and basic research.
|
|
|